Tuesday, September 8, 2015
Greenphire, a King of Prussia, Pa.-based provider of payment technology for the clinical trials industry, has announced that Duke University has selected its ClinCard system to support financial data management and tracking in more than 3,000 clinical studies that the organization conducts each year. As one of the largest biomedical research enterprises in the U.S., Duke will implement Greenphire’s solution to automate the management of payments, and associated data, it makes to research participants annually.
Burning Rock, a Guangzhou, China-based diagnostics company, has entered into an agreement to develop advanced clinical applications for molecular diagnostics in oncology based on Illumina’s next-generation sequencing (NGS) technology. The collaboration highlights the importance of genomics to improve healthcare in China.
Roche Pharma Research & Early Development (pRED) has developed a smartphone-based monitoring system for those with Parkinson’s disease (PD) that complements the traditional physician-led assessments with automated tests that continuously measure their symptom fluctuations. It could be the first time that such an app has been used to measure disease and symptom severity in a medicine development program in PD.
It is nearly impossible today to avoid the growing number of commercially available wearable devices capable of gathering health information. These devices—typically placed on a wrist, arm or chest—hold promise for collecting, transmitting and integrating objective experiential data in real time and in aiding the analysis of a much higher volume of data from a significantly larger number of patients. But based on interviews with industry professionals, the conceptual promise of wearable devices in clinical trials remains largely that. Adoption is in its very earliest stages.